Jesse2233
Senior Member
- Messages
- 1,942
- Location
- Southern California
In another thread @Jeremy C. put forward the idea that Ampligen's mechanism of action might be replicated by the interferon inducer Larifan. He shared a link, which contains the following summary.
Unlike other Ampligen analogues Ridostin or Polyguacil, Larifan seems to be available for purchase.
I'm curious if anyone knows whether or not Larifan has ever been used by an ME/CFS patient. I found no reference on PR or across the web other than @Hip and @heapsreal mentioning it in the context of other interferon inducers.
I'm also curious on the thoughts of our scientifically minded posters on whether Larifan could actually approach Ampligen's demonstrated effectivensss for a certain post viral, high nRnase subset.
------
This is my third post in a series on Ampligen.
See: Update in Ampligen availability in the US
And: What does Ampligen's effectiveness tell us in light of the latest research?
I'm intrigued with Amplgien because of the plethora of stories touting its effectiveness and its frustrating elusiveness
Larfian
Larifan is a double-stranded RNA (dsRNA) of natural origin obtained from bacteriophage-infected E.coli cells. It is a heterogeneous population of dsRNA molecules with the mean molecular mass of about 500 kDa and the average length of RNA is 400 nt/p. Larifan (dsRNA) has been developed as a new poly-functional and wide-spectrum medical drug for viral and oncological diseases.
Larifan possesses various biological activities like interferon - inducing, immunomodulating, antiviral, antitumoral and antimutagenic properties. These activities are a result of the action of the induced endogenous interferon, but they also may be provoked directly by the dsRNA molecule.
Some drug forms such as ointment and injection form are being produced for human use; clinical trial of suppositories is in progress.
Larifan clinical efficacy has been studied in different clinics and institutes of Latvia and previous USSR since the 80-ties of the last century. In human clinics Larifan is employed as an immunomodulator with antiviral and antitumoral activities. Its therapeutic antiviral effect has been demonstrated in the treatment of herpes (in Russian, Ukrainian, Latvian clinics), papilloma, respiratory a.o. virus infections.
Unlike other Ampligen analogues Ridostin or Polyguacil, Larifan seems to be available for purchase.
I'm curious if anyone knows whether or not Larifan has ever been used by an ME/CFS patient. I found no reference on PR or across the web other than @Hip and @heapsreal mentioning it in the context of other interferon inducers.
I'm also curious on the thoughts of our scientifically minded posters on whether Larifan could actually approach Ampligen's demonstrated effectivensss for a certain post viral, high nRnase subset.
------
This is my third post in a series on Ampligen.
See: Update in Ampligen availability in the US
And: What does Ampligen's effectiveness tell us in light of the latest research?
I'm intrigued with Amplgien because of the plethora of stories touting its effectiveness and its frustrating elusiveness